Brown, Lisle/Cummings, Inc. Guardant Health, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 285 shares of GH stock, worth $6,235. This represents 0.0% of its overall portfolio holdings.
Number of Shares
285
Previous 85
235.29%
Holding current value
$6,235
Previous $2.46 Million
166.31%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GH
# of Institutions
330Shares Held
113MCall Options Held
680KPut Options Held
1.66M-
Vanguard Group Inc Valley Forge, PA11.6MShares$255 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$246 Million0.01% of portfolio
-
Baillie Gifford & CO6.09MShares$133 Million0.14% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.5MShares$98.5 Million4.27% of portfolio
-
Capital International Investors Los Angeles, CA4.47MShares$97.8 Million0.03% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $2.24B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...